ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

netarsudil

Also written as “AR-13324 Ophthalmic Solution 0.02%”, “Netarsudil Ophthalmic Solution 0.02%” and “Netarsudil ophthalmic solution 0.02%”.

Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Fuchs' Endothelial Dystrophy · Corneal Edema, led by 2 companies.

Drug pageNetarsudil: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 10, 201920 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alcon180 open or runningphase 4since Jan 10, 2019Feb 5, 2012none ahead
Price Vision Groupits history only20 open or runningphase 3since May 30, 2019May 30, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Alcon only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Feb 5, 2012.

  1. Jul 31, 20142 phase 3 studies in Ocular HypertensionNCT02207621, NCT02207491
  2. Sep 16, 2014Phase 3 study in Ocular HypertensionNCT02246764 · 93 enrolled · United States
  3. Mar 12, 2015Phase 1 study in Healthy SubjectsNCT02406287 · 10 enrolled · United States
  4. Jun 9, 2015Named netarsudilINNProposed as its International Nonproprietary Name in WHO's List 113
  5. Sep 16, 2015Phase 3 study in Glaucoma, Open-AngleNCT02558374 · 708 enrolled · United States
  6. Aug 15, 2016Phase 2 study in Ocular HypertensionNCT02874846 · 12 enrolled · United States
  7. Jul 12, 2017Phase 2 study in Glaucoma, Open-AngleNCT03233308 · 20 enrolled · United States
  8. Aug 29, 2017Phase 3 study in Glaucoma, Open-AngleNCT03284853 · 436 enrolled · Austria, Belgium, Czechia and more
  9. Oct 13, 2017Phase 2 study in Glaucoma, Open-AngleNCT03310580 · 42 enrolled · United States
  10. Jan 10, 2019Phase 4 study in Glaucoma, Open-AngleNCT03808688 · 261 enrolled · United States
  11. Feb 15, 2019Phase 2 study in Glaucoma, Open-AngleNCT03844945 · 215 enrolled · Japan
  12. Jul 31, 2020Phase 2 study in Corneal EdemaNCT04498169 · 40 enrolled · United States
  13. Oct 26, 2020Phase 3 study in Glaucoma, Open-AngleNCT04620135 · 245 enrolled · Japan
  14. Mar 7, 2022Phase 4 study in GlaucomaNCT05283395 · 136 enrolled · United States
  15. Jul 17, 2025Phase 3 study in Ocular HypertensionNCT07082816 · 489 enrolled · United States

TargetBeta

ROCK1 →ROCK2 →read by rule
“Rho-associated protein kinase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
belumosudilruleSanofiphase 426

Studies

All 18 Alcon leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07082816Ocular Hypertension · United States3CompletedApr 6, 2026489
NCT05283395Glaucoma · United States4CompletedMar 22, 2023136
NCT04620135Glaucoma, Open-Angle · Japan3CompletedJul 9, 2021245
NCT04498169Corneal Edema · United States2CompletedAug 11, 202140
NCT03844945Glaucoma, Open-Angle · Japan2CompletedSep 19, 2019215
NCT03808688Glaucoma, Open-Angle · United States4CompletedJul 26, 2019261
NCT03310580Glaucoma, Open-Angle · United States2CompletedOct 25, 201842
NCT03284853Glaucoma, Open-Angle · Austria, Belgium, Czechia and more3CompletedNov 6, 2020436
NCT03233308Glaucoma, Open-Angle · United States2CompletedApr 19, 201820
NCT02874846Ocular Hypertension · United States2CompletedSep 201612
NCT02558374Glaucoma, Open-Angle · United States3CompletedDec 2016708
NCT02406287Healthy Subjects · United States1CompletedApr 201610
NCT02246764Ocular Hypertension · United States3CompletedDec 201693
NCT02207621Ocular Hypertension · United States3CompletedMar 2016756
NCT02207491Ocular Hypertension · United States3CompletedMar 2015411
NCT01997879Healthy · United States1CompletedNov 201318
NCT01731002Ocular Hypertension · United States2CompletedMay 2013224
NCT01528787Ocular Hypertension · United States2CompletedJul 201285

How it is read

Names in the registry

  • “AR-13324 Ophthalmic Solution 0.02%”, 7 entries
  • “Netarsudil Ophthalmic Solution 0.02%”, 3 entries
  • “Netarsudil ophthalmic solution 0.02%”, 2 entries
  • “Netarsudil Ophthalmic”, 2 entries
  • “AR-13324 Ophthalmic Solution 0.04%”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.